Top

Published in:

01-09-2018 | Review Article

Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery

Authors: Mohammad Mahmoudian, Sara Salatin, Ahmad Yari Khosroushahi

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Abstract

Lipoproteins (LPs) are a set of naturally occurring bio-nanoparticles consisting of Apo-LPs, phospholipids, a highly hydrophobic core of cholesteryl esters and triglycerides that participate mainly in the targeted transport of cholesteryl esters and other hydrophobic molecules through the bloodstream. They also are able to recognize specific receptors on normal and abnormal cells. Therefore, LPs represent a relevant tool for targeted delivery of cancer diagnostics and therapeutics due to their native biocompatibility, biodegradability, nano-scale size and receptor-mediated uptake. The circulating LPs are categorized into five classes, each with its own characteristic protein and lipid composition. Low-density LPs (LDL) and high-density LPs (HDL) are two major subclasses of LPs which were extensively subjected to attractive and versatile vehicles for targeted delivery of anticancer drugs. This study focus to highlight the potential applications of LDL and HDL bio-nanocarriers in the field of specific target drug delivery to cancer cells.

Khosroushahi AY, Naderi-Manesh H, Yeganeh H, Barar J, Omidi Y (2012) Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities. Journal of nanobiotechnology 10:2. https://doi.org/10.1186/1477-3155-10-2 CrossRefPubMedPubMedCentral

Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M (2017) Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. Colloids surfaces B Biointerfaces 159:629–638. https://doi.org/10.1016/j.colsurfb.2017.08.031 CrossRefPubMed

Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Kiafar F, Jelvehgari M (2017) Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles. Research in pharmaceutical sciences 12(1):1–14. https://doi.org/10.4103/1735-5362.199041 CrossRefPubMedPubMedCentral

Jansen M, Pfaffelhuber P, Hoffmann MM, Puetz G, Winkler K (2016) In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample. Journal of lipid research 57(5):882–893. https://doi.org/10.1194/jlr.M058446 CrossRefPubMedPubMedCentral

Hara T, Tan Y, Huang L (1997) In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. Proc Natl Acad Sci USA 94(26):14547–14552CrossRefPubMed

Chung NS, Wasan KM (2004) Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Advanced drug delivery reviews 56(9):1315–1334. https://doi.org/10.1016/j.addr.2003.12.003 CrossRefPubMed

Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ (2001) Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Advanced drug delivery reviews 47(2–3):251–276CrossRefPubMed

Song L, Li H, Sunar U, Chen J, Corbin I, Yodh AG, Zheng G (2007) Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. International journal of nanomedicine 2(4):767–774PubMedPubMedCentral

Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA (2010) High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 30 (2):169–176. https://doi.org/10.1161/atvbaha.108.179275

10.

Kim SH, Adhikari BB, Cruz S, Schramm MP, Vinson JA, Narayanaswami V (2015) Targeted intracellular delivery of resveratrol to glioblastoma cells using apolipoprotein E-containing reconstituted HDL as a nanovehicle. PloS one 10(8):e0135130. https://doi.org/10.1371/journal.pone.0135130 CrossRefPubMedPubMedCentral

11.

Kader A, Pater A (2002) Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. Journal of controlled release: official journal of the Controlled Release Society 80(1–3):29–44CrossRef

12.

Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP (2010) Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. International journal of pharmaceutics 391(1–2):313–321. https://doi.org/10.1016/j.ijpharm.2010.03.011 CrossRefPubMed

13.

Feng M, Cai Q, Huang H, Zhou P (2008) Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. European journal of pharmaceutics biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 68(3):688–693. https://doi.org/10.1016/j.ejpb.2007.07.005 CrossRef

14.

Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z (2005) High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World journal of gastroenterology 11(7):954–959CrossRefPubMedPubMedCentral

15.

Zheng G, Chen J, Li H, Glickson JD (2005) Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 102(49):17757–17762. https://doi.org/10.1073/pnas.0508677102 CrossRefPubMed

16.

Zhu C, Pradhan P, Huo D, Xue J, Shen S, Roy K, Xia Y (2017) Reconstitution of Low-Density Lipoproteins with Fatty Acids for the Targeted Delivery of Drugs into Cancer Cells. Angew Chem 56(35):10399–10402. https://doi.org/10.1002/anie.201704674 CrossRef

17.

Nami Y, Abdullah N, Haghshenas B, Radiah D, Rosli R, Khosroushahi AY (2014) Probiotic potential and biotherapeutic effects of newly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells. Anaerobe 28:29–36. https://doi.org/10.1016/j.anaerobe.2014.04.012 CrossRefPubMed

18.

Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R, Omidi Y (2012) Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers inhibit HT-29 colon cancer cell proliferation. Asian Pacific journal of cancer prevention: APJCP 13(9):4751–4756CrossRefPubMed

19.

Lelu S, Strand SP, Steine J, Davies Cde L (2011) Effect of PEGylation on the diffusion and stability of chitosan-DNA polyplexes in collagen gels. Biomacromol 12(10):3656–3665. https://doi.org/10.1021/bm200901s CrossRef

20.

Patil AJ, Li M, Dujardin E, Mann S (2007) Novel bioinorganic nanostructures based on mesolamellar intercalation or single-molecule wrapping of DNA using organoclay building blocks. Nano letters 7(9):2660–2665. https://doi.org/10.1021/nl071052q CrossRefPubMed

21.

McConathy WJ, Paranjape S, Mooberry L, Buttreddy S, Nair M, Lacko AG (2011) Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug delivery and translational research 1 (2):113–120. https://doi.org/10.1007/s13346-010-0012-0

22.

Sag D, Cekic C, Wu R, Linden J, Hedrick CC (2015) The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nature communications 6:6354. https://doi.org/10.1038/ncomms7354 CrossRefPubMedPubMedCentral

23.

Chowdhary RK, Sharif I, Chansarkar N, Dolphin D, Ratkay L, Delaney S, Meadows H (2003) Correlation of photosensitizer delivery to lipoproteins and efficacy in tumor and arthritis mouse models; comparison of lipid-based and Pluronic P123 formulations. Journal of pharmacy & pharmaceutical sciences: a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 6 (2):198–204

24.

Salatin S, Maleki Dizaj S, Yari Khosroushahi A (2015) Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int 39(8):881–890. https://doi.org/10.1002/cbin.10459 CrossRefPubMed

25.

Acton SL, Scherer PE, Lodish HF, Krieger M (1994) Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 269(33):21003–21009PubMed

26.

Becker L, Webb BA, Chitayat S, Nesheim ME, Koschinsky ML (2003) A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J Biol Chem 278(16):14074–14081. https://doi.org/10.1074/jbc.M212855200 CrossRefPubMed

27.

Weng W, Breslow JL (1996) Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci USA 93(25):14788–14794CrossRefPubMed

28.

Saballs M, Parra S, Sahun P, Pelleja J, Feliu M, Vasco C, Guma J, Borras JL, Masana L, Castro A (2016) HDL-c levels predict the presence of pleural effusion and the clinical outcome of community-acquired pneumonia. SpringerPlus 5(1):1491. https://doi.org/10.1186/s40064-016-3145-x CrossRefPubMedPubMedCentral

29.

Ishikawa H, Yamada H, Taromaru N, Kondo K, Nagura A, Yamazaki M, Ando Y, Munetsuna E, Suzuki K, Ohashi K, Teradaira R (2017) Stability of serum high-density lipoprotein-microRNAs for preanalytical conditions. Annals of clinical biochemistry 54(1):134–142. https://doi.org/10.1177/0004563216647086 CrossRefPubMed

30.

Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, Rothblat G, de la Llera-Moya M, Asztalos B, Perlman T, Zheng C, Alaupovic P, Maltais JA, Brewer HB (2009) Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. Journal of lipid research 50(5):894–907. https://doi.org/10.1194/jlr.M800622-JLR200 CrossRefPubMedPubMedCentral

31.

Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, Ugolkov AV, Singh AT, Dave SS, Gordon LI, Thaxton CS (2013) Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci USA 110(7):2511–2516. https://doi.org/10.1073/pnas.1213657110 CrossRefPubMed

32.

Li J, Wang J, Li M, Yin L, Li XA, Zhang TG (2016) Up-regulated expression of scavenger receptor class B type 1 (SR-B1) is associated with malignant behaviors and poor prognosis of breast cancer. Pathology research practice 212(6):555–559. https://doi.org/10.1016/j.prp.2016.03.011 CrossRef

33.

Schorghofer D, Kinslechner K, Preitschopf A, Schutz B, Rohrl C, Hengstschlager M,Stangl H, Mikula M (2015) The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence. Reproductive biology and endocrinology: RB&E 13:88. doi:10.1186/s12958-015-0087-z

34.

Gutierrez-Pajares JL, Ben Hassen C, Chevalier S, Frank PG (2016) SR-BI: Linking Cholesterol and Lipoprotein Metabolism with Breast and Prostate Cancer. Frontiers in pharmacology 7:338. https://doi.org/10.3389/fphar.2016.00338 CrossRefPubMedPubMedCentral

35.

Eberhart T, Eigner K, Filik Y, Fruhwurth S, Stangl H, Rohrl C (2016) The unfolded protein response is a negative regulator of scavenger receptor class B, type I (SR-BI) expression. Biochemical biophysical research communications 479(3):557–562. https://doi.org/10.1016/j.bbrc.2016.09.110 CrossRefPubMed

36.

Oliveira CL, Santos PR, Monteiro AM, Figueiredo Neto AM (2014) Effect of oxidation on the structure of human low- and high-density lipoproteins. Biophysical journal 106(12):2595–2605. https://doi.org/10.1016/j.bpj.2014.04.049 CrossRefPubMedPubMedCentral

37.

Nichols TC, Merricks EP, Bellinger DA, Raymer RA, Yu J, Lam D, Koch GG, Busby WH Jr, Clemmons DR (2015) Oxidized LDL and Fructosamine Associated with Severity of Coronary Artery Atherosclerosis in Insulin Resistant Pigs Fed a High Fat/High NaCl Diet. PloS one 10(7):e0132302. https://doi.org/10.1371/journal.pone.0132302 CrossRefPubMedPubMedCentral

38.

Li C, Zhang J, Wu H, Li L, Yang C, Song S, Peng P, Shao M, Zhang M, Zhao J, Zhao R, Wu W, Ruan Y, Wang L, Gu J (2017) Lectin-like oxidized low-density lipoprotein receptor-1 facilitates metastasis of gastric cancer through driving epithelial-mesenchymal transition and PI3K/Akt/GSK3beta activation. Scientific reports 7:45275. https://doi.org/10.1038/srep45275 CrossRefPubMedPubMedCentral

39.

Murdocca M, Mango R, Pucci S, Biocca S, Testa B, Capuano R, Paolesse R, Sanchez M, Orlandi A, di Natale C, Novelli G, Sangiuolo F (2016) The lectin-like oxidized LDL receptor-1: a new potential molecular target in colorectal cancer. Oncotarget 7(12):14765–14780. https://doi.org/10.18632/oncotarget.7430 CrossRefPubMedPubMedCentral

40.

van der Sluis RJ, Van Eck M, Hoekstra M (2015) Adrenocortical LDL receptor function negatively influences glucocorticoid output. The Journal of endocrinology 226(3):145–154. https://doi.org/10.1530/joe-15-0023 CrossRefPubMed

41.

Furuya Y, Sekine Y, Kato H, Miyazawa Y, Koike H, Suzuki K (2016) Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate international 4(2):56–60. https://doi.org/10.1016/j.prnil.2016.02.003 CrossRefPubMedPubMedCentral

42.

Bhuiyan H, Masquelier M, Tatidis L, Gruber A, Paul C, Vitols S (2017) Acute Myelogenous Leukemia Cells Secrete Factors that Stimulate Cellular LDL Uptake via Autocrine and Paracrine Mechanisms. Lipids 52(6):523–534. https://doi.org/10.1007/s11745-017-4256-z CrossRefPubMedPubMedCentral

43.

Reynolds L, Mulik RS, Wen X, Dilip A, Corbin IR (2014) Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine (London England) 9(14):2123–2141. https://doi.org/10.2217/nnm.13.187 CrossRef

44.

Lundberg B, Suominen L (1984) Preparation of biologically active analogs of serum low density lipoprotein. Journal of lipid research 25(6):550–558PubMed

45.

Matz CE, Jonas A (1982) Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem 257(8):4535–4540PubMed

46.

Bricarello DA, Smilowitz JT, Zivkovic AM, German JB, Parikh AN (2011) Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS nano 5(1):42–57. https://doi.org/10.1021/nn103098m CrossRefPubMed

47.

Bergt C, Fu X, Huq NP, Kao J, Heinecke JW (2004) Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein. J Biol Chem 279(9):7856–7866. https://doi.org/10.1074/jbc.M309046200 CrossRefPubMed

48.

Foroozesh M, Zarrin A (2010) A Safe, Versatile and Translation-prone Strategy for Using Circulating Lipoproteins as Endogenous Drug Delivery Systems. Journal of Medical Hypotheses Ideas 4:15

49.

Salatin S, Yari Khosroushahi A (2017) Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. Journal of cellular molecular medicine 21(9):1668–1686. https://doi.org/10.1111/jcmm.13110 CrossRefPubMed

50.

Bijsterbosch MK, Manoharan M, Dorland R, Waarlo IH, Biessen EA, van Berkel TJ (2001) Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein. Biochemical pharmacology 62(5):627–633CrossRefPubMed

51.

Attie AD, Pittman RC, Steinberg D (1980) Metabolism of native and of lactosylated human low density lipoprotein: evidence for two pathways for catabolism of exogenous proteins in rat hepatocytes. Proc Natl Acad Sci USA 77(10):5923–5927CrossRefPubMed

52.

Hrzenjak A, Frank S, Wo X, Zhou Y, Van Berkel T, Kostner GM (2003) Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism. The Biochemical journal 376(Pt 3):765–771. https://doi.org/10.1042/bj20030932 CrossRefPubMedPubMedCentral

53.

Thapa B, Kumar P, Zeng H, Narain R (2015) Asialoglycoprotein Receptor-Mediated Gene Delivery to Hepatocytes Using Galactosylated Polymers. Biomacromol 16(9):3008–3020. https://doi.org/10.1021/acs.biomac.5b00906 CrossRef

54.

Jain A, Jain K, Kesharwani P, Jain NK (2013) Low density lipoproteins mediated nanoplatforms for cancer targeting. Journal of nanoparticle research 15(9):1888CrossRef

55.

Carnemolla R, Ren X, Biswas TK, Meredith SC, Reardon CA, Wang J, Getz GS (2008) The specific amino acid sequence between helices 7 and 8 influences the binding specificity of human apolipoprotein A-I for high density lipoprotein (HDL) subclasses: a potential for HDL preferential generation. J Biol Chem 283(23):15779–15788. https://doi.org/10.1074/jbc.M710244200 CrossRefPubMedPubMedCentral

56.

Zhang X, Chen B (2010) Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer letters 298(1):26–33. https://doi.org/10.1016/j.canlet.2010.05.023 CrossRefPubMed

57.

Yuan Y, Wen J, Tang J, Kan Q, Ackermann R, Olsen K, Schwendeman A (2016) Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. International journal of nanomedicine 11:6229–6238. https://doi.org/10.2147/ijn.s112835 CrossRefPubMedPubMedCentral

58.

Murakami T, Wijagkanalan W, Hashida M, Tsuchida K (2010) Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine (London England) 5(6):867–879. https://doi.org/10.2217/nnm.10.66 CrossRef

59.

McMahon KM, Scielzo C, Angeloni NL, Deiss-Yehiely E, Scarfo L, Ranghetti P, Ma S, Kaplan J, Barbaglio F, Gordon LI, Giles FJ, Thaxton CS, Ghia P (2017) Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. Oncotarget 8(7):11219–11227. https://doi.org/10.18632/oncotarget.14494 CrossRefPubMedPubMedCentral

60.

Zhang F, Wang X, Xu X, Li M, Zhou J, Wang W (2016) Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. Eur J Pharm Sci 92:11–21CrossRefPubMed

61.

Subramanian C, Kuai R, Zhu Q, White P, Moon JJ, Schwendeman A, Cohen MS (2016) Synthetic high-density lipoprotein nanoparticles: A novel therapeutic strategy for adrenocortical carcinomas. Surgery 159(1):284–294. https://doi.org/10.1016/j.surg.2015.08.023 CrossRefPubMed

62.

Murakami T, Okamoto H, Kim H (2015) Structural and functional changes in high-density lipoprotein induced by chemical modification. Biomaterials science 3(5):712–715. https://doi.org/10.1039/c4bm00402g CrossRefPubMed

63.

Bijsterbosch MK, Van Berkel TJ (1992) Lactosylated high density lipoprotein: a potential carrier for the site-specific delivery of drugs to parenchymal liver cells. Molecular pharmacology 41(2):404–411PubMed

64.

Bijsterbosch MK, van de Bilt H, van Berkel TJ (1996) Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochemical pharmacology 52(1):113–121CrossRefPubMed

65.

Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, Fayad ZA (2010) RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24(6):1689–1699. https://doi.org/10.1096/fj.09-139865 CrossRef

66.

Liu L, He H, Zhang M, Zhang S, Zhang W, Liu J (2014) Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions. Biomaterials 35(27):8002–8014. https://doi.org/10.1016/j.biomaterials.2014.05.081 CrossRefPubMed

67.

Angeloni NL, McMahon KM, Swaminathan S, Plebanek MP, Osman I, Volpert OV, Thaxton CS (2016) Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1. Scientific reports 6:22915. https://doi.org/10.1038/srep22915 CrossRefPubMedPubMedCentral

68.

Shin JY, Yang Y, Heo P, Lee JC, Kong B, Cho JY, Yoon K, Shin CS, Seo JH, Kim SG, Kweon DH (2012) pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. International journal of nanomedicine 7:2805–2816. https://doi.org/10.2147/ijn.s29817 PubMedPubMedCentralCrossRef

69.

Baillie G, Owens MD, Halbert GW (2002) A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. Journal of lipid research 43(1):69–73PubMed

70.

Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM (2007) Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. Journal of controlled release: official journal of the Controlled Release Society 124(3):163–171. https://doi.org/10.1016/j.jconrel.2007.09.007 CrossRef

71.

Joniova J, Blascakova L, Jancura D, Nadova Z, Sureau F, Miskovsky P Incorporation of photosenzitizer hypericin into synthetic lipid-based nano-particles for drug delivery and large unilamellar vesicles with different content of cholesterol. SPIE NanoScience + Engineering, 2014. International Society for Optics and Photonics, 916604-916604-916612

72.

Su HT, Li X, Liang DS, Qi XR (2016) Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity. Oncotarget 7(32):51535–51552. https://doi.org/10.18632/oncotarget.10493 PubMedPubMedCentralCrossRef

73.

Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G (2007) Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J Am Chem Soc 129(18):5798–5799. https://doi.org/10.1021/ja069336k CrossRefPubMed

74.

Zuo L, Li L, Wang Q, Fleming TP, You S (2009) Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer cell international 9:8. https://doi.org/10.1186/1475-2867-9-8 CrossRefPubMedPubMedCentral

75.

Tauchi Y, Zushida L, Chono S, Sato J, Ito K, Morimoto K (2001) Effect of dexamethasone palmitate-low density lipoprotein complex on cholesterol ester accumulation in aorta of atherogenic model mice. Biological pharmaceutical bulletin 24(8):925–929CrossRefPubMed

76.

Pussinen PJ, Lindner H, Glatter O, Reicher H, Kostner GM, Wintersperger A, Malle E, Sattler W (2000) Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells. Biochimica et biophysica acta 1485(2–3):129–144CrossRefPubMed

77.

Masquelier M, Vitols S, Peterson C (1986) Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer research 46(8):3842–3847PubMed

78.

Samadi-Baboli M, Favre G, Canal P, Soula G (1993) Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice. British journal of cancer 68(2):319–326CrossRefPubMedPubMedCentral

79.

Hu J, Liu H, Wang L (2000) Enhanced delivery of AZT to macrophages via acetylated LDL. Journal of controlled release: official journal of the Controlled Release Society 69(3):327–335CrossRef

80.

Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG (2010) Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. Journal of drug targeting 18(1):53–58. https://doi.org/10.3109/10611860903156419 CrossRefPubMed

81.

McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG (2008) Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-cancer drugs 19(2):183–188. https://doi.org/10.1097/CAD.0b013e3282f1da86 CrossRefPubMed

82.

Lacko AG, Nair M, Paranjape S, Johnso S, McConathy WJ (2002) High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer research 22(4):2045–2049PubMed

83.

Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G (2013) Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (London England) 8(6):875–890. https://doi.org/10.2217/nnm.12.137 CrossRef

84.

Jain A, Jain K, Mehra NK, Jain N (2013) Lipoproteins tethered dendrimeric nanoconstructs for effective targeting to cancer cells. Journal of nanoparticle research 15(10):2003CrossRef

85.

86.

Bijsterbosch MK, Van Berkel TJ (1990) Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver. The Biochemical journal 270(1):233–239CrossRefPubMedPubMedCentral

87.

Schouten D, van der Kooij M, Muller J, Pieters MN, Bijsterbosch MK, van Berkel TJ (1993) Development of lipoprotein-like lipid particles for drug targeting: neo-high density lipoproteins. Molecular pharmacology 44(2):486–492PubMed

88.

Rensen PC, van Leeuwen SH, Sliedregt LA, van Berkel TJ, Biessen EA (2004) Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. Journal of medicinal chemistry 47(23):5798–5808. https://doi.org/10.1021/jm049481d CrossRefPubMed

89.

Shafi S, Cusack N, Born G (1989) Increased uptake of methylated low-density lipoprotein induced by noradrenaline in carotid arteries of anaesthetized rabbits. Proceedings of the Royal Society of London B: Biological Sciences 235 (1281):289–298

90.

Martín-Fuentes P, Civeira F, Recalde D, García-Otín AL, Jarauta E, Marzo I, Cenarro A (2007) Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J Immunol 179(5):3242–3248CrossRefPubMed

91.

Gillotte-Taylor K, Boullier A, Witztum JL, Steinberg D, Quehenberger O (2001) Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. Journal of lipid research 42(9):1474–1482PubMed

92.

Jinnouchi Y, Sano H, Nagai R, Hakamata H, Kodama T, Suzuki H, Yoshida M, Ueda S, Horiuchi S (1998) Glycolaldehyde-modified low density lipoprotein leads macrophages to foam cells via the macrophage scavenger receptor. Journal of biochemistry 123(6):1208–1217CrossRefPubMed

Title: Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery
Authors: Mohammad Mahmoudian
Sara Salatin
Ahmad Yari Khosroushahi
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3626-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients

A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib

Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer

Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer

Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer